The US Food and Drug Administration (FDA) has approved a lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.)-based combination therapy for the maintenance treatment of certain adults with ...

Two back-to-back papers published in Nature on Sept. 10, 2025, shed new light on the unexpected role of neurons in shaping the evolution of small-cell lung cancer (SCLC). It’s already known that, in ...

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine ...

Clinical data demonstrate the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients ...

(Barcelona, Spain-- September 8, 2025 at 5:00 PM CEST / UTC +2)— Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an ...

Small-cell lung cancer (SCLC) and some other cancers involve dysregulation of the transcription factor E2F, and apoptosis can be induced in those cells by blocking the interaction of the RxL sequence ...

Small cell lung cancer (SCLC) remains a highly aggressive malignancy with limited treatment options in the second-line setting, contributing to poor patient outcomes. Advances in therapeutic ...

A phase 2 trial found that compared with whole brain radiation (WBRT), stereotactic radiation reduced neurologic deaths in patients with small cell lung cancer (SCLC) and 1-10 brain metastases. SCLC ...

The global downturn in tobacco use has led to a significant decline in the number of patients who are diagnosed with small-cell lung cancer (SCLC) on a yearly basis. But for those who do have SCLC, ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited ...